Arcadia Biosciences (RKDA) Stock Forecast, Price & News

Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

Is Arcadia Biosciences a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences or view top-rated stocks.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 760,900 shares, a decrease of 25.4% from the April 15th total of 1,020,000 shares. Based on an average daily trading volume, of 2,180,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.6% of the company's stock are sold short.
View Arcadia Biosciences' Short Interest.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Arcadia Biosciences.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Wednesday, March, 30th. The basic materials company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.14. The basic materials company earned $2.17 million during the quarter, compared to the consensus estimate of $3.66 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 77.17% and a negative net margin of 231.20%. During the same quarter in the previous year, the company posted $0.01 earnings per share.
View Arcadia Biosciences' earnings history.

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Arcadia Biosciences's stock reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for RKDA?

1 equities research analysts have issued 1-year target prices for Arcadia Biosciences' shares. Their forecasts range from $3.50 to $4.00. On average, they expect Arcadia Biosciences' stock price to reach $3.75 in the next year. This suggests a possible upside of 209.9% from the stock's current price.
View analysts' price targets for Arcadia Biosciences or view top-rated stocks among Wall Street analysts.

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the following people:

• Ms. Pamela Haley, CFO & Corp. Sec. (Age 50, Pay $240k)
• Ms. Laura Pitlik, Chief Marketing Officer (Age 48, Pay $135.58k)
• Mr. Stanley E. Jacot Jr., Pres & CEO (Age 52)
• Ms. Belinda Yao, VP of Operations
• Mr. Brian Schaffer, Sr. VP of Sales
• Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 56)
• Mr. Kevin Hodges, VP of Commercial Operations

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences CEO Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among Arcadia Biosciences' employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcadia Biosciences' key competitors?

Some companies that are related to Arcadia Biosciences include S&W Seed (SANW), Origin Agritech (SEED), Margo Caribe (MRGO), Shineco (SISI), Scheid Vineyards (SVIN), Adecoagro (AGRO), AMAYA Global (AYAG), China Liaoning Dingxu Ecological Agriculture Development (CLAD), Hawaiian Macadamia Nut Orchards (NNUTU), Two Rivers Water & Farming (TURV), YaSheng Group (HERB) and Yew Bio-Pharm Group (YEWB).
View all of RKDA's competitors.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.45%), Renaissance Technologies LLC (0.35%), Jane Street Group LLC (0.16%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Cutler Group LP (0.00%).
View institutional ownership trends for Arcadia Biosciences.

Which institutional investors are selling Arcadia Biosciences stock?

RKDA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Cutler Group LP.
View insider buying and selling activity for Arcadia Biosciences or view top insider-selling stocks.

Which institutional investors are buying Arcadia Biosciences stock?

RKDA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Jane Street Group LLC, Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for Arcadia Biosciences or or view top insider-buying stocks.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $1.21.

How much money does Arcadia Biosciences make?

Arcadia Biosciences has a market capitalization of $26.85 million and generates $6.78 million in revenue each year. The basic materials company earns $-14.66 million in net income (profit) each year or ($0.960010) on an earnings per share basis.

How many employees does Arcadia Biosciences have?

Arcadia Biosciences employs 58 workers across the globe.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is www.arcadiabio.com.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at (530) 756-7077, via email at [email protected], or via fax at 530-756-7027.